Nu Skin Enterprises, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $240.5M
- Price
- $4.75
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.37%
- Volume
- 210.3K
About
Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
Quick stats
Shares outstanding48.7M
Computed float46.9M
Float / shares96.4%
Key info
SectorConsumer Defensive
IndustryHousehold & Personal Products
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001021561
Websitehttps://www.nuskin.com
AI Summary
AI-generated1/31
majorbearishearnings
Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2Q26
NU Skin reported 2Q26 revenue of $320.1M, missing the Stonegate estimate of $345.2M, while adjusted EPS of $0.20 matched expectations despite a weaker top line.
Management significantly lowered FY26 revenue guidance to $1.28B-$1.35B from $1.35B-$1.50B and reduced adjusted EPS guidance to $0.70-$0.90, citing a softer near-term setup.
The quarter included a $78.9M non-cash goodwill impairment and a $167.5M deferred-tax valuation allowance, while the India market launch was delayed to 1H27 to refine local operations.
Red flags
- Revenue missed estimates by approximately 7%
- Full-year revenue guidance cut by $150M at the top end
- $78.9M non-cash goodwill impairment recorded
- $167.5M deferred-tax valuation allowance recorded
- India market launch delayed to 1H27
- Nu Skin and Rhyz revenue declined 15.5% and 25.0% y/y respectively